Xi Zhu

No.1500 Zhouyuan Road
Pudong, 201318, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Salidroside impedes Ang II-infused myocardial fibrosis by activating the SIRT1-Nrf2 pathway.

Salidroside impedes Ang II-infused myocardial fibrosis by activating the SIRT1-Nrf2 pathway.

Journal: Iranian journal of basic medical sciences

Published: October 27, 2024

Targeting the sulfur-containing amino acid pathway in leukemia.

Targeting the sulfur-containing amino acid pathway in leukemia.

Journal: Amino acids

Published: April 06, 2024

Astragaloside IV inhibits angiotensin II-induced atrial fibrosis and atrial fibrillation by SIRT1/PGC-1α/FNDC5 pathway.

Astragaloside IV inhibits angiotensin II-induced atrial fibrosis and atrial fibrillation by SIRT1/PGC-1α/FNDC5 pathway.

Journal: Heliyon

Published: June 14, 2023

ANGPTL4 suppresses the profibrogenic functions of atrial fibroblasts induced by angiotensin II by up-regulating PPARγ.

ANGPTL4 suppresses the profibrogenic functions of atrial fibroblasts induced by angiotensin II by up-regulating PPARγ.

Journal: Iranian journal of basic medical sciences

Published: November 24, 2022

Stachydrine ameliorates hypoxia reoxygenation injury of cardiomyocyte via enhancing SIRT1-Nrf2 pathway.

Stachydrine ameliorates hypoxia reoxygenation injury of cardiomyocyte via enhancing SIRT1-Nrf2 pathway.

Journal: Journal of cardiothoracic surgery

Published: August 04, 2022

Interleukin-11 Is Elevated in Patients with Atrial Fibrillation, Correlates with Serum Fibrosis Markers, and Represents a Therapeutic Target for Atrial Fibrosis.

Interleukin-11 Is Elevated in Patients with Atrial Fibrillation, Correlates with Serum Fibrosis Markers, and Represents a Therapeutic Target for Atrial Fibrosis.

Journal: Cerebrovascular diseases (Basel, Switzerland)

Published: August 04, 2022

Inhibition of FABP4 attenuates cardiac fibrosis through inhibition of NLRP3 inflammasome activation.

Inhibition of FABP4 attenuates cardiac fibrosis through inhibition of NLRP3 inflammasome activation.

Journal: Iranian journal of basic medical sciences

Published: March 20, 2022

LOXL2 silencing suppresses angiotensin II-induced cardiac hypertrophy through the EMT process and TGF-β1/Smad3/NF-κB pathway.

LOXL2 silencing suppresses angiotensin II-induced cardiac hypertrophy through the EMT process and TGF-β1/Smad3/NF-κB pathway.

Journal: Iranian journal of basic medical sciences

Published: January 29, 2022

BRD4 Silencing Protects Angiotensin II-Induced Cardiac Hypertrophy by Inhibiting TLR4/NF-κB and Activating Nrf2-HO-1 Pathways.

BRD4 Silencing Protects Angiotensin II-Induced Cardiac Hypertrophy by Inhibiting TLR4/NF-κB and Activating Nrf2-HO-1 Pathways.

Journal: Cardiology research and practice

Published: December 12, 2021

Meta-Analysis of Catheter Ablation versus Medical Therapy for Heart Failure Complicated with Atrial Fibrillation.

Meta-Analysis of Catheter Ablation versus Medical Therapy for Heart Failure Complicated with Atrial Fibrillation.

Journal: Cardiology research and practice

Published: June 14, 2021

ANGPTL4 Attenuates Ang II-Induced Atrial Fibrillation and Fibrosis in Mice via PPAR Pathway.

ANGPTL4 Attenuates Ang II-Induced Atrial Fibrillation and Fibrosis in Mice via PPAR Pathway.

Journal: Cardiology research and practice

Published: March 06, 2021

Relationship between serum angiopoietin-like 4 levels and recurrence of atrial fibrillation.

Relationship between serum angiopoietin-like 4 levels and recurrence of atrial fibrillation.

Journal: The Journal of international medical research

Published: March 01, 2021

Showing 1-12 of 12

Last Updated: 09/26/2026